Author

R. A. Albrecht

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Organism:multiple species· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. Garcia-Sastre· 3 shared F. Krammer· 3 shared W.-C. Liu· 3 shared C. Marizzi· 2 shared D. A. Meekins· 2 shared E. K. Roubidoux· 2 shared R. McMahon· 2 shared R. Rathnasinghe· 2 shared

Activity by Year

2020-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Garcia-Sastre

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Detection of clade 2.3.4.4b highly pathogenic H5N1 influenza virus in New York City

P. S. Meade, P. Bandawane, K. Bushfield, I. Hoxie, K. R. Azcona, D. Burgos, S. Choudhury, A. Diaby, M. Diallo, K. Gaynor, A. Huang, K. Kante, S. N. Khan, W. Kim, P. Kehinde Ajayi, , C. Marizzi

The paper detects H5N1 clade 2.3.4.4b influenza viruses in urban birds in New York City and highlights the urban animal-human interface as a potential zoonotic risk.

bioRxiv · Apr 4, 2024Microbiology

Detection of velogenic avian paramyxoviruses in rock doves in New York City, New York

I. Francisco, S. Bailey, T. Bautista, D. Diallo, J. Gonzalez, J. Gonzalez, E. K. Roubidoux, P. K. Ajayi, R. A. Albrecht, R. McMahon, F. Krammer, C. Marizzi

The paper screens wild birds in NYC for APMV-1, identifies two isolates, and classifies them into genotype VI, highlighting their potential role in NDV outbreaks.

bioRxiv · Nov 2, 2021Microbiology

SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage

A. Escalera, A. S. Gonzalez-Reiche, S. Aslam, I. Mena, R. L. Pearl, M. Laporte, A. Fossati, R. Rathnasinghe, H. Alshammary, A. van de Guchte, M. Bouhaddou, T. Kehrer, L. Zuliani-Alvarez, D. A. Meekins, V. Balaraman, , T. Aydillo

This study shows SARS-CoV-2 variants of concern have mutations that increase spike cleavage and fusogenic capacity, enhancing viral transmission and cell entry.

bioRxiv · Aug 5, 2021 · PreprintMicrobiology

Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and death in animal models.

J. S. Y. Ho, B. W.-Y. Mok, L. Campisi, T. Jordan, S. Yildiz, S. Parameswaran, J. A. Wayman, N. N. Gaudreault, D. A. Meekins, S. V. Indran, I. Morozov, J. D. Trujillo, Y. S. Fstkchyan, R. Rathnasinghe, Z. Zhu, , Jeya

This study shows that Top1 inhibition with Topotecan reduces SARS-CoV-2-induced inflammation and mortality in animal models.

bioRxiv · Dec 1, 2020 · PreprintMicrobiology

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine

W. Sun, S. McCroskery, W.-C. Liu, S. R. Leist, Y. Liu, R. A. Albrecht, S. Slamanig, J. Oliva, F. Amanat, A. Schaefer, K. H. Dinnon, B. L. Innis, A. Garcia-Sastre, F. Krammer, R. S. Baric, P. Palese

This paper evaluates an inactivated Newcastle disease virus expressing the SARS-CoV-2 spike protein as a cost-effective vaccine, showing immunogenicity and protective efficacy in animal models.

bioRxiv · Jul 30, 2020Microbiology

Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics

L. Si, H. Bai, M. Rodas, W. Cao, C. Y. Oh, A. Jiang, R. Moller, D. Hoagland, K. Oishi, S. Horiuchi, S. Uhl, D. Blanco-Melo, R. A. Albrecht, W.-C. Liu, T. Jordan, , D. E. Ingber

This paper demonstrates the use of human organ chips to rapidly repurpose therapeutics for viral pandemics, identifying amodiaquine as a potential treatment for SARS-CoV-2.

bioRxiv · Apr 13, 2020 · PreprintMicrobiology